Meeting Coverage


Transcatheter Valve Therapy

Real-World Data Affirms Next-Gen TAVR Device Advantage

TVT registry compares outcomes with Evolut FX and Pro+

TVT over a photo of the Phoenix Convention Center.

Latest TVT Meeting Coverage

Strategies May Cut Pacing Needs With Navitor TAVR

Approval study analysis suggests best practices

June 11, 2023
Poor Nutrition Status Linked With Survival After MitraClip

But procedure no less effective for this higher risk group, COAPT trial post hoc analysis shows

June 10, 2023
Transapical Transcatheter Mitral Valve Replacement Trial Raises Questions

Pooled 2-year data show risks, raise concern about impact on ventricles

June 9, 2023
MitraClip Shines in Real-World, Core-Lab Data

Benefits similar across anatomical complexity, advanced heart failure in post-marketing studies

June 9, 2023
Novel LAA Closure Device 'Promising'

First-in-human experience weighs in on device that twists the left atrial appendage closed

June 8, 2023
TAVR Pacemaker Rate Dips to Single Digits Nationwide, but Outlier Hospitals Remain

Do worst-performing sites need more education about best practices?

June 12, 2022
Fate of Transcatheter Tricuspid Devices: Will it Be Repair or Replacement?

Many unanswered questions remain regarding devices for tricuspid regurgitation

June 11, 2022
TAVR Devices Keep Changing -- Is This Really Helping Patients?

Clinical outcomes are headed in the right direction, but better research is needed

June 10, 2022
Promising First Dips Into a Bigger Pool of MitraClip Candidates

Real-world outcomes in people with secondary MR who don't fit COAPT criteria

June 9, 2022
Surprising Tradeoffs of Valve-in-Valve TAVR vs Redo Surgery

Observational study suggests excess readmissions with less invasive procedure

July 23, 2021
Watchman FLX Stays on Track for Stroke Prevention

Next-generation LAA occluder maintains good results at 2 years

July 22, 2021
Does COAPT Change the Need to Try Foundational HF Drugs in Functional MR?

Current GDMT titration approach under fire during TVT debate

July 21, 2021
After Some Early Successes for Bicuspid TAVR, a Randomized Trial May Be Unlikely

Are observational data on highly selected patients good enough?

July 21, 2021
Sapien 3 TAVR On Par with Surgery at 5 Years

Differences observed in stroke and pacemaker rates

June 21, 2020